Lv1
10 积分 2023-07-03 加入
Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): a single-arm, phase II study
7小时前
待确认
Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study
7小时前
已完结
Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor
2个月前
已完结
Resistance Mechanisms to Anti-PD Cancer Immunotherapy
2个月前
已完结
Treg-mediated acquired resistance to immune checkpoint inhibitors
2个月前
已完结
Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial
2个月前
已完结
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
3个月前
已完结
Advancements in immunotherapy for gastric cancer: Unveiling the potential of immune checkpoint inhibitors and emerging strategies
3个月前
已完结
New Therapies on the Horizon
3个月前
已关闭
Enhancing anti-tumour efficacy with immunotherapy combinations
3个月前
已完结
皖公网安备34019202002308
